Oxford BioDynamics (OBD) Competitors

Oxford BioDynamics (LON:OBD) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Which has stronger valuation & earnings, OBD or HEMO?

Hemogenyx Pharmaceuticals has lower revenue, but higher earnings than Oxford BioDynamics. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford BioDynamics	£176K	137.57	-£10.83M	-£0.07	-110.91
Hemogenyx Pharmaceuticals	N/A	N/A	-£6.69M	-£0.01	-146.40

Is OBD or HEMO more profitable?

Hemogenyx Pharmaceuticals' return on equity of -222.31% beat Oxford BioDynamics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford BioDynamics	N/A	-250.52%	-46.27%
Hemogenyx Pharmaceuticals	N/A	-222.31%	-61.24%

Does the media prefer OBD or HEMO?

In the previous week, Oxford BioDynamics had 2 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 3 mentions for Oxford BioDynamics and 1 mentions for Hemogenyx Pharmaceuticals. Oxford BioDynamics' average media sentiment score of 0.13 beat Hemogenyx Pharmaceuticals' score of 0.00 indicating that Oxford BioDynamics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oxford BioDynamics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hemogenyx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility and risk, OBD or HEMO?

Oxford BioDynamics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, Hemogenyx Pharmaceuticals has a beta of 3.05, suggesting that its stock price is 205% more volatile than the S&P 500.

Does the MarketBeat Community favor OBD or HEMO?

Oxford BioDynamics received 49 more outperform votes than Hemogenyx Pharmaceuticals when rated by MarketBeat users. Likewise, 61.54% of users gave Oxford BioDynamics an outperform vote while only 57.89% of users gave Hemogenyx Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Oxford BioDynamics	Outperform Votes 104 61.54%	Underperform Votes 65 38.46%
Hemogenyx Pharmaceuticals	Outperform Votes 55 57.89%	Underperform Votes 40 42.11%

Do analysts recommend OBD or HEMO?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford BioDynamics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Hemogenyx Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Do insiders and institutionals hold more shares of OBD or HEMO?

36.5% of Oxford BioDynamics shares are held by institutional investors. Comparatively, 0.8% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 15.5% of Oxford BioDynamics shares are held by company insiders. Comparatively, 10.7% of Hemogenyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Oxford BioDynamics beats Hemogenyx Pharmaceuticals on 9 of the 13 factors compared between the two stocks.